Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifetroban in Duchenne Muscular Dystrophy
NCT03340675Phase 2Completed
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifetroban in Duchenne muscular dystrophy (DMD), sponsored by Cumberland Pharmaceuticals. Started Oct 2020; status: completed.
02
Drugs
ifetroban
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03340675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340675.